- The American Society of Clinical Oncology (ASCO) has released recommendations for the treatment of early-stage colorectal cancer (CRC) based on a systematic review of 12 existing guidelines.
Why this matters
- New guidelines provide recommendations for different resource settings.
- Stage I-III colon cancer optimal treatment:
- Most patients are treated with surgery, either laparoscopic or open resection along with draining nodal stages.
- Postsurgical chemotherapy, when available, is an option for patients with stage III tumors and high-risk stage II tumors.
- Adjuvant chemotherapy should be used in cases of high-risk obstructing colon cancer.
- Stage I-III rectal cancer treatment:
- The primary mode of treatment is surgery, with the specific procedure depending on the resource-level setting.
- Chemotherapy and/or radiotherapy is recommended, based on availability and potential risk factors, for patients with clinically resectable cT3N0 rectal cancer, high-risk stage II rectal cancer, and all patients with stage III rectal cancer. Preoperative risk factors should determine use of neoadjuvant therapy.
- Posttreatment surveillance for CRC:
- Follow-up should include medical history, physical examinations, carcinoembryonic antigen testing, imaging, and surveillance endoscopy. The follow-up frequency and other details depend on cancer stage and resource setting.
- Additional data, including evidence tables, is available online.